1.Saladini F, Giammarino F, Maggiolo F, et al.. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. Int J Antimicrob Agents. 2023
Articolo scientificoInt J Antimicrob AgentsLeggi il PDF gratuito
2.Lo Caputo, S., Poliseno, M., Tavelli, A., Gagliardini, R., Rusconi, S., Lapadula, G., Antinori, A., Francisci, D., Sarmati, L., Gori, A., Spagnuolo, V., Ceccherini-Silberstein, F., d'Arminio Monforte, A., Cozzi-Lepri, A., & ICONA Foundation Study Group (2024). Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2024
Articolo scientificoInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious DiseasesLeggi il PDF gratuito
3.Campagna R, Nonne C, Antonelli G, Turriziani O.. Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV. Viruses. 2024
Articolo scientificoVirusesLeggi il PDF gratuito

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).

Competenze

Di sistema: In italy, about 90% of people living with hiv (pwh) on treatment have a suppressed viral load. However, highly treatment-experienced (hte) pwh, who represent 1-10% of all pwh, are at higher risk of virological failure and clinical progression. In addition, hte pwh often require complex regimens with multiple drugs and multiple routes of administration, increasing the risk of drug interactions and adverse events. Prolonged art exposure leads to accumulated toxicities and, in combination with ageing and inflammation, increases the risk of metabolic and oncological comorbidities. This course will review strategies for optimising art in this population, focusing on the role of resistance testing in guiding treatment decisions. It will also discuss the role of new drugs with novel mechanisms of action that offer promising solutions to overcome resistance and simplify regimens for this challenging population.

Obiettivo formativo

#3Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

Area: Obiettivi formativi tecnico-professionali

Dettagli tecnici

Partecipanti max: 100
Verifica presenza: Firma Di PresenzaSistema Elettronico A Badges
Verifica apprendimento: Questionario A Risposta Multipla

Gratuitonessun costo di iscrizione

Inizio21 mag 2025

2crediti ECM assegnati

LuogoPADOVA, VENETO

Topics

Sede del Corso

Informazioni sulla Sede

Struttura: PADOVA CONGRESS
Indirizzo: VIA N. TOMMASEO, 59
Città: PADOVA
Regione: VENETO

Ottieni Indicazioni